Adlai Nortye Ltd.
Adlai Nortye Ltd. (ANL): 10 pipeline candidates · ~4 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
3.6 months
D/E 1.80
Lead: Phase 3
10 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for Adlai Nortye Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$729.6M
Cash
$60.9M
Quarterly Burn
$51.8M
Runway
3.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| an0025 | Phase 1 |
| an2025 | Phase 3 |
| an4005-dose level 0 | Phase 1 |
| an4005-dose level 1 | Phase 1 |
| an4005-dose level 2 | Phase 1 |
| an4005-dose level 3 | Phase 1 |
| an4005-dose level 4 | Phase 1 |
| an4005-food effect | Phase 1 |
| an8025 is a multifunctional antibody fusion protein | Phase 1 |
| an9025 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$23.3M
| Holder | Shares | Value |
|---|---|---|
| balyasny asset management l.p. | 877,846 | $6.1M |
| millennium management llc | 681,775 | $4.7M |
| adage capital partners gp, l.l.c. | 538,461 | $3.7M |
| superstring capital management lp | 414,852 | $2.9M |
| affinity asset advisors, llc | 164,748 | $1.1M |
| ubs group ag | 122,261 | $846K |
| ameriprise financial inc | 120,156 | $831K |
| adar1 capital management, llc | 117,909 | $816K |
| tidal investments llc | 66,034 | $457K |
| renaissance technologies llc | 66,000 | $457K |
Showing top 10 of 21 institutional holders of Adlai Nortye Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Adlai Nortye Ltd.'s pipeline?
Adlai Nortye Ltd. (ANL) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adlai Nortye Ltd.'s lead drug candidate?
Adlai Nortye Ltd.'s most advanced tracked candidate is an0025 (Phase 1) for Locally Advanced Solid Tumor.
What is Adlai Nortye Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adlai Nortye Ltd. has approximately 3.6 months of cash runway.
What is Adlai Nortye Ltd.'s market capitalization?
Adlai Nortye Ltd.'s market capitalization is approximately $729.6M.
Who is the CEO of Adlai Nortye Ltd.?
Mr. Yang Lu EMBA is the chief executive officer of Adlai Nortye Ltd. (ANL).
Get the full picture on Adlai Nortye Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.